Skip to content
Screener

AOCI at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$33.9M-21.1%
ALN
Alnylam PharmaceuticalsALNY
-$32.14M-7.3%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$368K-45.5%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
-$48.2M-0.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0+100%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$1.07M-769%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemMarch 31, 2026September 30, 2025
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value:Authorized 290,000 shares; 143,232 shares issued and 140,571 outstanding as of March 31, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025236231
Additional paid-in capital2,395,2672,139,725
Accumulated other comprehensive income7426,443
Accumulated deficit(1,729,075)(1,627,154)
Treasury stock; at cost; 2,661 shares of common stock at March 31, 2026 and September 30, 2025(53,193)(53,193)
Stockholders’ equity613,977466,052
Noncontrolling interest(15,061)37,364

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's AOCI?
Arrowhead Research (ARWR) reported AOCI of $742K in Q1 2026.
How has Arrowhead Research's AOCI changed year-over-year?
Arrowhead Research's AOCI decreased by 83.1% year-over-year, from $4.39M to $742K.
What is the long-term trend for Arrowhead Research's AOCI?
Over 4 years (2021 to 2025), Arrowhead Research's AOCI has grown at a 210.9% compound annual growth rate (CAGR), from -$69K to $6.44M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ask your AI about Arrowhead Research's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude